Onc

Quote
I launched this drug
At first we had huge uptake being TNBC and demand. But quickly on patient feedback to Oncologists & withdraw at rapid rate -9out of 10--it hasnt done anything and stuck at 100million. I am looking internal &,external at other divisions.
 






anonymous said:
Very true
Tell tell sign is not 1 KITE Oncology employee has applied and we all know how hard a sell inner cellular agents are since Gilead bought us. But at least we dont have an agent that is so dirty with side effects that patient have to quit after 1 dose & go back to combo treatment for a quality of life.
There has been many drugs developed that worked great but make the patient miserable & they are dogs. Many of times your block buster oncology agents are the ones that work pretty good but are clean w little side effects.
Trodelvia is not one!
Flat or negative sales first couple yrs of launch is not good. 99% time ends in being a BUST.
Click to expand...

All complete BS. Trodelvy is an excellent therapy!
 






anonymous said:
I launched this drug
At first we had huge uptake being TNBC and demand. But quickly on patient feedback to Oncologists & withdraw at rapid rate -9out of 10--it hasnt done anything and stuck at 100million. I am looking internal &,external at other divisions.
Click to expand...


We know that's not true. An oncology rep would never look at any other division here.

Trodelvy is doing just fine with its limited indication. Once the indications grow, so will Trodelvy. Feedback from customers is uniformly positive. The biggest issue is Covid.
 






anonymous said:
We know that's not true. An oncology rep would never look at any other division here.

Trodelvy is doing just fine with its limited indication. Once the indications grow, so will Trodelvy. Feedback from customers is uniformly positive. The biggest issue is Covid.
Click to expand...


Thank you for the honest feedback. Is this a POD situation, or will reps get to manage their own territories? Thanks.
 






anonymous said:
We know that's not true. An oncology rep would never look at any other division here.

Trodelvy is doing just fine with its limited indication. Once the indications grow, so will Trodelvy. Feedback from customers is uniformly positive. The biggest issue is Covid.
Click to expand...
It is not doing fine. Has zero growth. Not growing ,& Gilead paid a big prem.
Ask any Oncologists and 8 out 10 patients can not tolerate 1st dose & switch......
Works good but makes you feel like dying.
Doing 100mil this year but flat last 6 months.
2022 goal is 550million (500% increase).

You wonder why most of the Oncology mgt team, NSD, ERD, RDs have bolted and last 4wks reps are bailing.
If was so great wonder drug & docs using hand over fists, nobody would leave.
I am selling it and it is a hard dam as s sell!
Straight Up candid. Its not efficacy, its the nasty side effects, when docs getting calls o. 24/7 living in bathroom vomiting guts out & leaving trail of sh i t all over house, Houston thats a problem & no doc will force pt to stay on that wants to switch.
I.G sold Gilead swamp land. Merck's TNBC drug as good without side effects & 500 reps will be launching it.
 












anonymous said:
It is not doing fine. Has zero growth. Not growing ,& Gilead paid a big prem.
Ask any Oncologists and 8 out 10 patients can not tolerate 1st dose & switch......
Works good but makes you feel like dying.
Doing 100mil this year but flat last 6 months.
2022 goal is 550million (500% increase).

You wonder why most of the Oncology mgt team, NSD, ERD, RDs have bolted and last 4wks reps are bailing.
If was so great wonder drug & docs using hand over fists, nobody would leave.
I am selling it and it is a hard dam as s sell!
Straight Up candid. Its not efficacy, its the nasty side effects, when docs getting calls o. 24/7 living in bathroom vomiting guts out & leaving trail of sh i t all over house, Houston thats a problem & no doc will force pt to stay on that wants to switch.
I.G sold Gilead swamp land. Merck's TNBC drug as good without side effects & 500 reps will be launching it.
Click to expand...
Oncology rep in North. This is true.
The drug had bunch fan fare being for TNBC with efficacy data but real world post launch it has ran into a wall with thousands being put on therapy only to drop off by the 2nd dose. Many the 1st dose.... due to nasty side effects.
AZ TNBC drug doesn't have our SE plus with 300 more reps, will be the gold standard.
We are not growing & starting to see decline due to patient compliance & rapid negative patient word of mouth.
I am just thrilled to make 7 figures on the Gilead buyout & complete the retention bonus period. Like my existing colleagues, I will start looking after the holidays.
(Above comment about Gilead buying bill of goods that was really swamp land is true. They were sold a story & bought it hook line sinker )
 


















anonymous said:
It is not doing fine. Has zero growth. Not growing ,& Gilead paid a big prem.
Ask any Oncologists and 8 out 10 patients can not tolerate 1st dose & switch......
Works good but makes you feel like dying.
Doing 100mil this year but flat last 6 months.
2022 goal is 550million (500% increase).

You wonder why most of the Oncology mgt team, NSD, ERD, RDs have bolted and last 4wks reps are bailing.
If was so great wonder drug & docs using hand over fists, nobody would leave.
I am selling it and it is a hard dam as s sell!
Straight Up candid. Its not efficacy, its the nasty side effects, when docs getting calls o. 24/7 living in bathroom vomiting guts out & leaving trail of sh i t all over house, Houston thats a problem & no doc will force pt to stay on that wants to switch.
I.G sold Gilead swamp land. Merck's TNBC drug as good without side effects & 500 reps will be launching it.
Click to expand...

where did they bolt to?
 






Who bolt???

They only had like 30 reps who became instant millionaires on the buyout 18months ago then stayed for retention bonus that just expired.
The NSD & ED along with 2 RDs left for an Oncology start up co.
 












anonymous said:
Oncology rep in North. This is true.
The drug had bunch fan fare being for TNBC with efficacy data but real world post launch it has ran into a wall with thousands being put on therapy only to drop off by the 2nd dose. Many the 1st dose.... due to nasty side effects.
AZ TNBC drug doesn't have our SE plus with 300 more reps, will be the gold standard.
We are not growing & starting to see decline due to patient compliance & rapid negative patient word of mouth.
I am just thrilled to make 7 figures on the Gilead buyout & complete the retention bonus period. Like my existing colleagues, I will start looking after the holidays.
(Above comment about Gilead buying bill of goods that was really swamp land is true. They were sold a story & bought it hook line sinker )
Click to expand...

This person does not sell this drug. I do and this post is complete BS. First, the drug is a really good drug. Worth $20b? Probably not but patients do quite well and can tolerate the SE’s, nothing better in 2L mTNBC. If you are considering a job here, the top reason would be this is a great treatment with still a lot of potential. Second, reps are not leaving bc the product sucks. They are leaving because they don’t want to work in a POD with reps with little experience to no oncology background and other startups are hiring. Last, nobody I know here would brag about making 7 figures in the buyout to people on cafepharma.

Currently, we have lost our ED of sales because his position got split into two and one manager who went to Mirati. We have also lost maybe around 10 of the 50(not 30 or whatever other numbers have been incorrectly referenced). They are going to other startups, G1, AADI. Will probably use a handful more to Mirati. However, this is a great place to start or continue a short oncology career, great product and benefits (Excellent 401k match, ESPP, RSU’s, 2 shutdowns, etc)
 






anonymous said:
This person does not sell this drug. I do and this post is complete BS. First, the drug is a really good drug. Worth $20b? Probably not but patients do quite well and can tolerate the SE’s, nothing better in 2L mTNBC. If you are considering a job here, the top reason would be this is a great treatment with still a lot of potential. Second, reps are not leaving bc the product sucks. They are leaving because they don’t want to work in a POD with reps with little experience to no oncology background and other startups are hiring. Last, nobody I know here would brag about making 7 figures in the buyout to people on cafepharma.

Currently, we have lost our ED of sales because his position got split into two and one manager who went to Mirati. We have also lost maybe around 10 of the 50(not 30 or whatever other numbers have been incorrectly referenced). They are going to other startups, G1, AADI. Will probably use a handful more to Mirati. However, this is a great place to start or continue a short oncology career, great product and benefits (Excellent 401k match, ESPP, RSU’s, 2 shutdowns, etc)
Click to expand...
You are about 20% accurate w this info.
The rest you are full of S@*#&
There are currently 35 reps reps with a dozen openings
There will not be PODs for 1 product LMOA idiot. It is single point of accountability with Solo territories.
I dont think the poster said she/he got 7 figures on buyout but rather reference others, which is accurate as that is actually normal for a startup buyout premium Gilead paid.
People are leaving because they CASHED in as of last month & going to do it again or retire early, BUT main reason is we had a typical start up Oncology co & all Gilead knows is typical Micro Manage HR/Legal ruled company with their only experience in clinic settings.
Thus ALL they focus on is Calls Freq Reach Programs getting 12 calls a day & 1 program a month.
They have no clue about this space & being drill sergeants with Pres Johanna leading the way.
I am looking as well as most others after the holidays.
Good for you if you want to stay in a Primary Care High Compliance Call Activity driven company. You are now a millionaire on paper if you came from IG so best luck to you.
Also 3 friends have taken our drug on my advise and 2 dropped off after 1st dose & 3rd after 2nd dose. Real World Side effects are nasty. We probably messed with the data to get a buyout offer.
20 Billion a yr ???? You are on crack & herio at same time. 100mil now, no way will do more than 300mil peak yrs as both Merck & AZ agents look golden & alot cleaner
 






anonymous said:
This person does not sell this drug. I do and this post is complete BS. First, the drug is a really good drug. Worth $20b? Probably not but patients do quite well and can tolerate the SE’s, nothing better in 2L mTNBC. If you are considering a job here, the top reason would be this is a great treatment with still a lot of potential. Second, reps are not leaving bc the product sucks. They are leaving because they don’t want to work in a POD with reps with little experience to no oncology background and other startups are hiring. Last, nobody I know here would brag about making 7 figures in the buyout to people on cafepharma.

Currently, we have lost our ED of sales because his position got split into two and one manager who went to Mirati. We have also lost maybe around 10 of the 50(not 30 or whatever other numbers have been incorrectly referenced). They are going to other startups, G1, AADI. Will probably use a handful more to Mirati. However, this is a great place to start or continue a short oncology career, great product and benefits (Excellent 401k match, ESPP, RSU’s, 2 shutdowns, etc)
Click to expand...

OK HR thanks for adding another layer of BS. This company is the afterbirth of where we started.
Every day good people leave and dimwits in HR fill the spots with anybody with a pulse. If you need a job or are looking for short term employment. It’s not that bad but it’s not great.
 






anonymous said:
You are about 20% accurate w this info.
The rest you are full of S@*#&
There are currently 35 reps reps with a dozen openings
There will not be PODs for 1 product LMOA idiot. It is single point of accountability with Solo territories.
I dont think the poster said she/he got 7 figures on buyout but rather reference others, which is accurate as that is actually normal for a startup buyout premium Gilead paid.
People are leaving because they CASHED in as of last month & going to do it again or retire early, BUT main reason is we had a typical start up Oncology co & all Gilead knows is typical Micro Manage HR/Legal ruled company with their only experience in clinic settings.
Thus ALL they focus on is Calls Freq Reach Programs getting 12 calls a day & 1 program a month.
They have no clue about this space & being drill sergeants with Pres Johanna leading the way.
I am looking as well as most others after the holidays.
Good for you if you want to stay in a Primary Care High Compliance Call Activity driven company. You are now a millionaire on paper if you came from IG so best luck to you.
Also 3 friends have taken our drug on my advise and 2 dropped off after 1st dose & 3rd after 2nd dose. Real World Side effects are nasty. We probably messed with the data to get a buyout offer.
20 Billion a yr ???? You are on crack & herio at same time. 100mil now, no way will do more than 300mil peak yrs as both Merck & AZ agents look golden & alot cleaner
Click to expand...
This is TRUE
Gilead has zero clue about Oncology and IG while a startup wasnt the best, it was 1000x better than Gilead with basic Oncology.
Gilead Miss President and our Oncology VP are are a JOKE. Get a rep job for 12 months to understand the F ing dynamics that you both are making decisions on!
You all think your S@(#&#( smells great!
1 piece of advice-- ONCOLOGY IS NOT A CLINIC BASE PRIMARY CARE MODEL DRUG LIKE YOUR HIV & HEP DRUGS THAT ANY PC PERSON CAN SELL. Oncology is extremely competitive & its not just about if a drug works well, its about Patient Tolerability & Compliance
Gilead has the wrong people involved to lead this ship! Like others, I have my recruiters lined up & will start interviewing in Jan
 












Unfortunate to hear that Dan O coming from a big onc company like Genentech/Roche let’s this happen on his watch. Then again, the days of the big onc products that he oversaw are long over.
 


















Top Bottom
Back
Quote